ABSI

Absci Corporation NASDAQ

Healthcare ·Biotechnology ·US · absci.com

$5.62

Pre-mkt $5.70 +1.42%

Mkt Cap $873.6M

52w Low $2.24 98.5% of range 52w High $5.67

50d MA $3.14 200d MA $3.19

P/E (TTM) -5.9x

EV/EBITDA -4.1x

P/B 3.5x

Debt/Equity 0.0x

ROE -60.8%

P/FCF -5.1x

RSI (14) —

ATR (14) —

Beta 2.01

50d MA $3.14

200d MA $3.19

Avg Volume 4.0M

About

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headqua…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 24, 2026	AMC	-0.16	-0.23	-43.8%	3.01	-3.7%	-3.0%	-4.3%	-7.6%	-8.3%	-0.3%	—
Nov 12, 2025	AMC	-0.19	-0.20	-5.3%	3.40	-12.4%	-22.4%	-17.1%	-15.9%	-16.5%	-15.9%	—
Aug 12, 2025	AMC	-0.19	-0.24	-26.3%	2.97	-4.4%	+5.1%	+1.0%	-1.3%	-4.7%	-11.8%	—
May 13, 2025	AMC	-0.23	-0.21	+8.7%	2.96	+22.0%	-1.7%	+0.0%	-2.7%	-6.4%	-5.7%	—
Mar 18, 2025	AMC	-0.22	-0.25	-13.6%	3.08	-2.6%	-3.2%	-1.3%	-2.3%	+0.6%	-0.3%	—
Nov 12, 2024	AMC	-0.19	-0.24	-26.3%	3.64	+2.5%	-13.7%	-17.0%	-22.0%	-23.9%	-25.3%	—
Aug 14, 2024	AMC	-0.19	-0.22	-15.8%	3.73	+0.3%	+11.0%	+7.5%	+11.8%	+13.4%	+16.6%	—
May 14, 2024	AMC	-0.19	-0.22	-15.8%	4.83	+2.7%	+0.0%	-1.9%	-4.3%	-4.6%	-0.8%	—
Mar 21, 2024	AMC	-0.23	-0.25	-8.7%	5.28	+0.0%	-6.2%	-4.2%	-1.3%	+4.9%	+7.6%	—
Nov 14, 2023	AMC	-0.23	-0.24	-4.3%	1.40	-7.1%	+0.0%	-0.7%	+3.6%	+4.3%	-2.9%	—
Aug 14, 2023	AMC	-0.24	-0.27	-12.5%	1.77	+1.1%	-7.3%	-9.6%	-6.2%	-5.1%	-5.6%	—
May 15, 2023	AMC	-0.24	-0.26	-8.3%	1.28	+5.5%	-8.6%	-5.9%	-7.8%	+8.6%	+41.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 30	Needham	Maintains	Buy → Buy	—	$2.78	$2.75	-1.1%	-0.7%	+7.9%	+13.3%	+10.1%	+6.5%
Mar 25	Needham	Maintains	Buy → Buy	—	$3.01	$2.90	-3.7%	-3.0%	-4.3%	-7.6%	-8.3%	-0.3%
Mar 18	Needham	Maintains	Buy → Buy	—	$3.03	$2.92	-3.6%	-5.6%	+1.7%	-2.3%	-3.3%	-0.7%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.39	$3.48	+2.7%	+0.6%	-0.3%	+8.3%	+3.8%	+5.0%
Dec 12	Needham	Maintains	Buy → Buy	—	$3.84	$3.83	-0.3%	-5.2%	-11.7%	-7.6%	-11.7%	-11.2%
Nov 13	Needham	Maintains	Buy → Buy	—	$3.40	$2.98	-12.4%	-22.4%	-17.1%	-15.9%	-16.5%	-15.9%
Aug 18	Morgan Stanley	Maintains	Overweight → Overweight	—	$2.93	$2.90	-1.0%	-3.4%	-10.6%	-12.3%	-12.6%	-10.2%
Aug 13	Needham	Maintains	Buy → Buy	—	$2.97	$2.84	-4.4%	+5.1%	+1.0%	-1.3%	-4.7%	-11.8%
Jul 28	Morgan Stanley	Maintains	Overweight → Overweight	—	$2.89	$3.04	+5.2%	+2.8%	+2.1%	+1.0%	-2.1%	+0.3%
May 14	Needham	Maintains	Buy → Buy	—	$2.96	$3.61	+22.0%	-1.7%	+0.0%	-2.7%	-6.4%	-5.7%
Apr 16	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$3.12	$3.11	-0.3%	-2.2%	-1.0%	-1.6%	+2.9%	+2.2%
Apr 9	Needham	Maintains	Buy → Buy	—	$2.27	$2.21	-2.6%	+13.7%	+8.4%	+33.0%	+36.1%	+37.4%
Mar 20	Guggenheim	Maintains	Buy → Buy	—	$2.98	$2.94	-1.3%	+2.0%	+1.0%	+4.0%	+3.0%	-2.7%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.08	$3.00	-2.6%	-3.2%	-1.3%	-2.3%	+0.6%	-0.3%
Mar 19	Needham	Maintains	Buy → Buy	—	$3.08	$3.00	-2.6%	-3.2%	-1.3%	-2.3%	+0.6%	-0.3%
Jan 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.80	$2.86	+2.1%	+3.6%	+15.0%	+43.9%	+48.9%	+42.9%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.22	$3.08	-4.3%	-11.2%	-11.5%	-15.8%	-11.2%	-13.0%
Jan 8	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$3.07	$4.09	+33.2%	+4.9%	-6.8%	-7.2%	-11.7%	-6.8%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.07	$4.09	+33.2%	+4.9%	-6.8%	-7.2%	-11.7%	-6.8%
Dec 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.68	$3.73	+1.4%	+0.5%	+4.1%	-9.5%	-17.4%	-20.7%
Dec 3	Guggenheim	Maintains	Buy → Buy	—	$3.15	$3.15	+0.0%	-5.1%	-1.9%	-7.3%	-1.3%	+1.9%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.64	$3.73	+2.5%	-13.7%	-17.0%	-22.0%	-23.9%	-25.3%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.73	$3.74	+0.3%	+11.0%	+7.5%	+11.8%	+13.4%	+16.6%
Jul 11	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$3.61	$3.69	+2.2%	+11.6%	+11.6%	+9.4%	+20.5%	+21.3%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.83	$4.96	+2.7%	+0.0%	-1.9%	-4.3%	-4.6%	-0.8%
Mar 26	Truist	Maintains	Buy → Buy	—	$5.06	$5.11	+1.0%	+3.0%	+9.5%	+12.3%	+10.9%	+1.6%
Mar 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.28	$5.28	+0.0%	-6.2%	-4.2%	-1.3%	+4.9%	+7.6%
Mar 6	Truist	Maintains	Buy → Buy	—	$5.26	$5.70	+8.4%	+1.9%	-2.5%	-4.6%	-10.6%	-6.1%
Mar 4	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$5.46	$5.74	+5.1%	+5.1%	-3.7%	-1.8%	-6.0%	-8.1%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.62	$3.62	+0.0%	+15.5%	+13.5%	+21.5%	+14.1%	+10.2%
Jan 5	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$3.72	$3.89	+4.6%	-2.7%	+12.4%	+10.5%	+18.3%	+11.0%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.40	$1.30	-7.1%	+0.0%	-0.7%	+3.6%	+4.3%	-2.9%
Aug 16	Truist	Maintains	Buy → Buy	—	$1.64	$1.64	+0.0%	-2.4%	+1.2%	+2.4%	+1.8%	-7.3%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.77	$1.79	+1.1%	-7.3%	-9.6%	-6.2%	-5.1%	-5.6%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.28	$1.35	+5.5%	-8.6%	-5.9%	-7.8%	+8.6%	+41.4%
May 16	Credit Suisse	Maintains	Outperform → Outperform	—	$1.28	$1.35	+5.5%	-8.6%	-5.9%	-7.8%	+8.6%	+41.4%
May 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.25	$1.31	+4.8%	+4.8%	+11.2%	+13.6%	+6.0%	+4.8%
Aug 12	JP Morgan	Downgrade	Overweight → Underweight	—	$4.79	$5.13	+7.1%	-0.2%	+0.8%	-4.4%	-9.6%	-11.7%
Aug 12	Credit Suisse	Maintains	Outperform → Outperform	—	$4.79	$5.13	+7.1%	-0.2%	+0.8%	-4.4%	-9.6%	-11.7%
Aug 12	Cowen & Co.	Upgrade	Market Perform → Outperform	—	$4.79	$5.13	+7.1%	-0.2%	+0.8%	-4.4%	-9.6%	-11.7%
Jul 18	Truist	Maintains	Buy → Buy	—	$3.38	$3.60	+6.5%	-0.3%	+5.9%	+7.7%	+6.2%	-0.3%
May 31	Stifel	Maintains	Hold → Hold	—	$3.87	$3.91	+1.0%	-5.7%	-9.0%	-0.5%	-5.9%	-13.2%
Mar 23	Credit Suisse	Maintains	Outperform → Outperform	—	$7.48	$7.45	-0.4%	+0.7%	+11.4%	+2.9%	+1.5%	+12.4%
Feb 1	Berenberg	Maintains	Buy → Buy	—	$6.73	$7.05	+4.8%	+7.6%	+9.7%	+3.4%	+7.0%	+9.7%
Nov 10	BofA Securities	Downgrade	Neutral → Underperform	—	$14.23	$13.21	-7.2%	-9.4%	-8.9%	-21.4%	-20.4%	-15.2%
Aug 16	Stifel	Maintains	Hold → Hold	—	$25.01	$24.50	-2.0%	-15.7%	-22.0%	-18.0%	-18.0%	-10.0%
Aug 16	BofA Securities	Maintains	Neutral → Neutral	—	$25.01	$24.50	-2.0%	-15.7%	-22.0%	-18.0%	-18.0%	-10.0%
Aug 16	Cowen & Co.	Maintains	Market Perform → Perform	—	$25.01	$24.50	-2.0%	-15.7%	-22.0%	-18.0%	-18.0%	-10.0%
Aug 16	Credit Suisse	Maintains	Outperform → Outperform	—	$25.01	$24.50	-2.0%	-15.7%	-22.0%	-18.0%	-18.0%	-10.0%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Absci's rapid progression of AI-designed ABS-201 into human trials with positive safety signals validates its platform technology, potentially justifying higher valuations if clinical efficacy data continues to impress investors.

Mar 24

8-K · 5.02 !!! Very High

Absci Corporation -- 8-K 5.02: Executive Change

Absci Corporation will lose director Andreas Busch on March 31, 2026, potentially affecting board oversight and decision-making capabilities.

Mar 6

Data updated apr 24, 2026 10:17am · Source: massive.com